Menu Search
Equities

IGC Pharma Inc

IGS1:STU

IGC Pharma Inc

Actions
  • Price (EUR)0.278
  • Today's Change0.014 / 5.30%
  • Shares traded0.00
  • 1 Year change-24.04%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year IGC Pharma Inc had net income fall 12.98% from a loss of 11.51m to a larger loss of 13.00m despite a 47.64% increase in revenues from 911.00k to 1.35m.
Gross margin60.36%
Net profit margin-1,252.64%
Operating margin-1,261.77%
Return on assets-101.29%
Return on equity-126.20%
Return on investment-122.91%
More ▼

Cash flow in USDView more

In 2024, cash reserves at IGC Pharma Inc fell by 2.00m. Cash Flow from Financing totalled 3.52m or 262.01% of revenues. In addition the company used 5.20m for operations while cash used for investing totalled 317.00k.
Cash flow per share-0.1985
Price/Cash flow per share--
Book value per share0.1042
Tangible book value per share0.0814
More ▼

Balance sheet in USDView more

IGC Pharma Inc uses little debt in its capital structure as supported by a debt to capital ratio of 1.73%.
Current ratio1.77
Quick ratio1.16
Total debt/total equity0.0176
Total debt/total capital0.0173
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.